Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   16/05/2025
59,27 USD (+1,72%)
(+1,72%)   16/05/2025
Grafiek Biomarin Pharmaceutical Inc. Grafiek Biomarin Pharmaceutical Inc.

Biomarin Pharmaceutical Inc. in het nieuws

12 mei 2025 · BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings · Persbericht

1 mei 2025 · BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance · Persbericht

17 april 2025 · BioMarin to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 4:30pm ET · Persbericht

2 april 2025 · BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria · Persbericht

20 maart 2025 · BioMarin Presents New Data Demonstrating Favorable Safety and Strong Adherence in Real-World Clinical Practice with VOXZOGO® (vosoritide) in Children Under 3 with Achondroplasia at 2025 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

4 september 2024 · BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance · Persbericht

4 september 2024 · BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time · Persbericht

29 augustus 2024 · BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY · Persbericht

21 augustus 2024 · BioMarin Announces New R&D and Business Development Leadership · Persbericht

19 augustus 2024 · BioMarin to Host 2024 Investor Day on September 4th in New York · Persbericht

Profiel Biomarin Pharmaceutical Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.bmrn.com

Hoofdzetel: Novato, California vlag Verenigde Staten

CEO: Jean-Jacques Bienaime

Werknemers: 3.902

Mijn selecties